Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProMIS Neurosciences Inc. (Nasdaq: PMN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, proxy statements and other key documents. ProMIS is a clinical-stage biotechnology company focused on antibody and vaccine candidates targeting toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases, and its filings offer detailed insight into corporate actions, governance and clinical program updates.
Through recent Form 8-K filings, ProMIS has reported material events such as the implementation of a one-for-twenty-five reverse stock split of its common shares, effective November 28, 2025, and subsequent notification from Nasdaq that the company regained compliance with the $1.00 minimum bid price requirement. Other 8-Ks describe the recommendation of an independent Data and Safety Monitoring Board to advance the PRECISE-AD Phase 1b trial of PMN310 to the final dose escalation cohort, the establishment of an at-the-market offering program, and the appointment and compensation of directors and executives.
The company’s definitive proxy statement on Schedule 14A outlines matters submitted to shareholders, including authorization of the share consolidation and procedures for a virtual special meeting. These materials provide information on share structure proposals, voting results and corporate governance practices. Additional filings reference press releases reporting quarterly financial results, which are incorporated by reference into Item 2.02 of Form 8-K.
On Stock Titan, ProMIS filings are updated in line with EDGAR and can be reviewed alongside AI-powered summaries that explain the significance of each document. Investors can quickly see how reverse stock split mechanics, Nasdaq listing compliance, at-the-market offerings, and clinical trial milestones are described in official filings. Over time, this page will also aggregate annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 as they are filed, helping users track both the scientific and capital markets dimensions of PMN’s development.
Form 4 filing for ProMIS Neurosciences (PMN) shows 10% owner Michael S. Gordon, via Title 19 Promis LLC, increasing his indirect stake.
- 25 Jul 2025: Exercised Tranches A–C warrants (119,800 shares each, total 359,400) at a reduced price of $0.83158 versus original $2.02/$2.50 strikes, lifting common-share holdings to 2,435,029.
- 29 Jul 2025: Purchased 539,100 new five-year warrants at a purchase price of $0.1875 per warrant; each is exercisable at $1.25 for one common share.
Gordon now holds 345,316 derivative securities plus the common shares noted. The actions signal insider commitment and supply up to 898,500 potential new shares, implying moderate dilution if all warrants are exercised.
On 21 Jul 2025 ProMIS Neurosciences (PMN) filed an 8-K disclosing two material items.
- ATM program terminated: The Company and BTIG mutually ended the US$25 m at-the-market agreement first signed 5 Jan 2024. Only 75,862 shares were sold for gross proceeds of US$190,274, leaving US$24.8 m unused. No termination penalties apply and no further shares will be issued under this facility.
- Pipeline progress: The FDA granted Fast Track Designation to PMN310, ProMIS’s lead monoclonal antibody for Alzheimer’s disease. A Data & Safety Monitoring Board has authorised escalation to the 10 mg/kg cohort in the ongoing Phase 1b trial, and, as of 21 Jul 2025, no amyloid-related imaging abnormalities (ARIA) have been observed.
The filing contains no financial results, but it removes potential equity dilution from the ATM, while regulatory momentum for PMN310 could shorten the development timeline.